An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
Status: Recruiting
Location: See all (6) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• 1\. Participants must have biopsy-confirmed IgA Nephropathy
Locations
United States
Florida
Site-003
RECRUITING
Miami Lakes
Site-005
RECRUITING
Pembroke Pines
Illinois
Site-009
RECRUITING
Hinsdale
Missouri
Site-006
RECRUITING
Chesterfield
South Dakota
Site-002
RECRUITING
Dakota Dunes
Texas
Site-004
RECRUITING
Houston
Contact Information
Primary
Chief Medical Officer
clinicaltrials@biohavenpharma.com
203-404-0410
Time Frame
Start Date: 2025-07-30
Estimated Completion Date: 2026-07
Participants
Target number of participants: 10
Treatments
Experimental: BHV-1400
Related Therapeutic Areas
Sponsors
Leads: Biohaven Therapeutics Ltd.